| Summary: | The article discusses various aspects of health insurance and pharmaceuticals as examined in the November issue of Health Affairs. Key findings include the high costs of employer-sponsored health insurance, with average family premiums at $25,572, and significant out-of-pocket expenses for Medicare enrollees, particularly in traditional Medicare compared to Medicare Advantage plans. The article also highlights the impact of Medicaid eligibility determinations post-COVID-19, the availability of dental coverage, and the implications of the Inflation Reduction Act on drug price negotiations. Additionally, it addresses the challenges in the adoption of immunization requirements across states.
|
|---|